

DAFTAR PUSTAKA

- Abidoye, O., Ahn, D. H., Borad, M. J., Wu, C., Bekaii-Saab, T., Chakrabarti, S., & Sonbol, M. B. (2025). Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer. *Cells*, 14(3), 161. <https://doi.org/10.3390/cells14030161>
- Abraham D. (1973). Mathematical statistics. *Proceedings of the 1st Annual Computer Science Conference on Program Information Abstracts - CWC '73*, 25–26. <https://doi.org/10.1145/1125118.1125129>
- ACS. (2019). Breast Cancer Facts & Figures 2019-2020. In *American Cancer Society*. American Cancer Society.
- Afifah, A., & Purnami, S. (2016). Uji Proportional Hazard Pada Penderita Kanker Serviks Di RSUD Dr. Soetomo Surabaya. *Jurnal Sains Dan Seni ITS*, 5, 109–114.
- Afifi, I., Maruddani, D., & Hoyyi, A. (2017). Analisis Ketahanan Hidup Penderita Dengue Hemorrhagic Fever (Demam Berdarah) Dengan Regresi Cox Kegagalan Proportional Sensor Tipe III. *Gaussian*, 6, 365–374.
- Afranda, O., Wuryandari, T., & Ispiyanti, D. (2015). Analisis Regresi Proportional Dari Cox Pada Data Waktu Tunggu Sarjana. *Gaussian*, 4(3), 621–630.
- Alava, M., Wailoo, A., Grimm, S., Pudney, S., Gomes, M., Sadique, Z., & et al. (2018). EQ-5D-5L Versus EQ-5D-3L: The Impact On Cost Effectiveness In The United Kingdom. *Value in Health*, 21(1), 49–56. <https://doi.org/10.1016/j.jval.2017.09.004>
- Aldi, Y., Wahyuni, F., Dillasamola, D., Badriyya, E., & Srangenge, Y. (2023). Serologi Imunologi. In *NBER Working Papers*. Andalas University Press.
- Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., Perou, C. M., Regan, M. M., Rimm, D. L., Symmans, W. F., Torlakovic, E. E., Varella, L., Viale, G., Weisberg, T. F., McShane, L. M., & Wolff, A. C. (2020). Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. *J Clin Oncol*, 38(12), 1346–1366. <https://doi.org/10.1200/JCO.19.02309>
- Alsoulami, L., Shawagfeh, S., Abdi, A., & Basgut, B. (2020a). Efficacy And Safety Of Capecitabine Alone Or In Combination In Advanced Metastatic Breast Cancer Patients Previously Treated With Anthracycline And Taxane: A Systematic Review And Meta-

- Analysis. In *Oncology research and treatment* (Vol. 43, Number 12, pp. 694–702). <https://doi.org/10.1159/000510356>
- Alzehr, A., Hulme, C., Spencer, A., & Morgan-Trimmer, S. (2022). The economic impact of cancer diagnosis to individuals and their families: a systematic review. *Supportive Care in Cancer*, 30(8), 6385–6404. <https://doi.org/10.1007/s00520-022-06913-x>
- Andayani, T., Endarti, D., Kristina, S., & Rahmawati, A. (2020). Perbandingan EQ-5D-5L Dan SF-6D Untuk Mengukur Index Utility Kesehatan Pada Populasi Umum Di Yogyakarta. *J Manaj Farm*, 10(1), 35–44.
- Andayani, T., Endarti, D., Kristina, S., & Rokhman, M. (2017). Metode Untuk Memperkirakan Willingness-To-Pay Per Quality Adjusted Life Year Sebagai Cost-Effectiveness Threshold. *Jurnal Manajemen Dan Pelayanan Farmasi Per*, 7(3), 142–147.
- Angraini, D., Semiatry, R., Rasyid, R., & Khambri, D. (2018). Faktor-Faktor Yang Mempengaruhi Kualitas Hidup Penderita Kanker Payudara Di Kota Padang. *Jurnal Endurance*, 3(3), 562–567. <https://doi.org/10.22216/jen.v3i3.3094>
- Anmar R. Raheem, O. F. A.-R. O. S. K. A. Z. A. H. A. A. (2023). Diagnostic and differential efficacy of cyclin D1 and CA15-3 in breast cancer and benign breast tumors. *Journal of Angiotherapy*, 7(1). <https://doi.org/10.25163/angiotherapy.717335>
- Arnold, R. J. G. (2020). *Pharmacoeconomics: Form Theory To Practice* (2nd ed.). CRC Press.
- Ashariati, A. (2019). *Manajemen Kanker Payudara Komprehensif*. Airlangga University Press.
- Badan Penelitian dan Pengembangan Kesehatan Kementerian RI. (2018). *Riset Kesehatan Dasar Tahun 2018*.
- Badan Pusat Statistik. (2024). *Ekonomi Indonesia Triwulan IV-2023 Tumbuh 5,04 Persen (y-on-y)*. <https://www.bps.go.id/pressrelease/2024/02/05/2379/ekonomi-indonesia-triwulan-iv-2023-tumbuh-5-04-persen--y-on-y-.html>.
- Bae, S., Lee, J., & Bae, E.-Y. (2022). How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea. *Frontiers in Pharmacology*, 13. <https://doi.org/10.3389/fphar.2022.884769>
- Barrios, C. H. (2022). Global challenges in breast cancer detection and treatment. *The Breast*, 62, S3–S6. <https://doi.org/10.1016/j.breast.2022.02.003>
- Bartsch, R., Singer, C. F., Pfeiler, G., Hubalek, M., Stoeger, H., Pichler, A., Petru, E., Bjelic-Radisic, V., Greil, R., Rudas, M., Muiy-Kheng, T. M., Wette, V., Petzer, A. L., Sevela,

- P., Egle, D., Dubsky, P. C., Filipits, M., Fitzal, F., Exner, R., ... Gnant, M. (2021). Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. *British Journal of Cancer*, 124(11), 1795–1802. <https://doi.org/10.1038/s41416-021-01284-2>
- Bertram, M., Lauer, J., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P., & Hill, S. (2016). Cost–effectiveness thresholds: pros and cons. *Bulletin of the World Health Organization*, 94(12), 925–930. <https://doi.org/10.2471/BLT.15.164418>
- Bloom, D., Chen, S., McGovern, M., Prettnner, K., Candeias V, Bernaert A, & et al. (2015). Economics Of Non-Communicable Diseases In Indonesia. In *World Economic Forum* (Number April).
- Bootman, J., Townsend, R., & Mcghan, W. (1996). *Introduction To Pharmacoeconomics dalam Principles Of Pharmacoeconomics*. Harvey Whitney Books Company.
- Botlagunta, M., Botlagunta, M. D., Myneni, M. B., Lakshmi, D., Nayyar, A., Gullapalli, J. S., & Shah, M. A. (2023). Classification and diagnostic prediction of breast cancer metastasis on clinical data using machine learning algorithms. *Scientific Reports*, 13(1), 485. <https://doi.org/10.1038/s41598-023-27548-w>
- Bourke, S., Bennett, B., Oluboyede, Y., Li, T., Longworth, L., O’Sullivan, S. B., Braverman, J., Soare, I.-A., & Shaw, J. W. (2024). Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer. *Health and Quality of Life Outcomes*, 22(1), 81. <https://doi.org/10.1186/s12955-024-02294-3>
- Braybrooke, J., Bradley, R., Gray, R., Hills, R. K., Pan, H., Peto, R., Dodwell, D., McGale, P., Taylor, C., Aihara, T., Anderson, S., Blum, J., Cardoso, F., Chen, X., Crown, J. P., Ejlersen, B., Friedl, T. W. P., Harbeck, N., Janni, W., ... Swain, S. M. (2023a). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. *The Lancet*, 401(10384), 1277–1292. [https://doi.org/10.1016/S0140-6736\(23\)00285-4](https://doi.org/10.1016/S0140-6736(23)00285-4)
- Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., André, F., Barrios, C., Bergh, J., Bonnefoi, H., Bretel Morales, D., Brucker, S., Burstein, H., Cameron, D., Cardoso, F., ... Xu, B. (2021). Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. *Ann Oncol*, 32(10), 1216–1235. <https://doi.org/10.1016/j.annonc.2021.06.023>
- Butnari, V., Scantlebury, P., Green, T., Pattni, D., Mansuri, A., Chinnery, W., Rajendran, N., Brannan, M., Cole, M., & Banerjee, S. (2025). The crucial role of early diagnosis for patients and the nation, understanding the costs of late-stage cancer diagnosis from a

large district general hospital in England. *Cost Effectiveness and Resource Allocation*, 23(1), 60. <https://doi.org/10.1186/s12962-025-00657-1>

Caplan, L. (2014). Delay in Breast Cancer: Implications for Stage at Diagnosis and Survival. *Frontiers in Public Health*, 2. <https://doi.org/10.3389/fpubh.2014.00087>

Centanni, M., Nijhuis, J., Karlsson, M. O., & Friberg, L. E. (2025a). Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy. *Pharmacoeconomics*, 43(1), 31–43. <https://doi.org/10.1007/s40273-024-01438-z>

Chen, H., Zhou, M., Tian, W., Meng, K., & He, H. (2016). Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database. *PLOS ONE*, 11(10), e0165409. <https://doi.org/10.1371/journal.pone.0165409>

Chen, H., & Zhou, Q. (2023). Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review). *Oncology Reports*, 49(5), 106. <https://doi.org/10.3892/or.2023.8543>

Chen, W., Tu, Q., Shen, Y., Tang, K., Hong, M., & Shen, Y. (2021). Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer. *World Journal of Surgical Oncology*, 19(1), 52. <https://doi.org/10.1186/s12957-021-02150-4>

Chin, Y. M., Shibayama, T., Chan, H. T., Otaki, M., Hara, F., Kobayashi, T., Kobayashi, K., Hosonaga, M., Fukada, I., Inagaki, L., Ono, M., Ito, Y., Takahashi, S., Ohno, S., Ueno, T., Nakamura, Y., & Low, S. (2022). Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. *Cancer Science*, 113(5), 1808–1820. <https://doi.org/10.1111/cas.15304>

Choulli, F., Tafenzi, H. A., Hattimy, F. EL, Choulli, M. K., & Belbaraka, R. (2024). Chemotherapy-related adverse effects with anthracycline and taxane-containing regimens in patients with localized Breast cancer: a descriptive study. *BMC Cancer*, 24(1), 17. <https://doi.org/10.1186/s12885-023-11616-5>

Chye, A., Jan, S., Pathy, N. B., Luna, H. G. C., Lim, S. B., Kimman, M., Woodward, M., Peters, S., Monaghan, H., Ngelangel, C. A., & Angell, B. (2025). Modelling the health, financial protection and equity impacts of upscaling the ACT NOW early intervention breast cancer pilot program in the Philippines: an extended cost-effectiveness analysis. *BMJ Global Health*, 10(2), e016402. <https://doi.org/10.1136/bmjgh-2024-016402>

Cimbro, E., Dessì, M., Ziranu, P., Madeddu, C., Atzori, F., Lai, E., Pretta, A., Mariani, S., Donisi, C., Spanu, D., Pozzari, M., Murgia, S., Saba, G., Codipietro, C., Palmas, E., Sanna, G., Semonella, F., Sardo, S., Finco, G., & Scartozzi, M. (2024). Early taxane exposure and neurotoxicity in breast cancer patients. *Supportive Care in Cancer*, 32(10), 709. <https://doi.org/10.1007/s00520-024-08908-2>

- Dahan, M., Hequet, D., Bonneau, C., Paoletti, X., & Rouzier, R. (2021). Has tumor doubling time in breast cancer changed over the past 80 years? A systematic review. *Cancer Medicine*, 10(15), 5203–5217. <https://doi.org/10.1002/cam4.3939>
- Dahlan, M. (2012). *Analisis Survival: Dasar-Dasar Teori & Aplikasi*. Epidemiologi Indonesia.
- Dang, D. K., & Park, B. H. (2022). Circulating tumor DNA: current challenges for clinical utility. *Journal of Clinical Investigation*, 132(12). <https://doi.org/10.1172/JCI154941>
- Daniel, O., Ashrafi, A., Muthoni, M. A., Njoki, N., Eric, H., Marilyn, O., Faith, A. B., Beth, W. G., Nyakio, M., Odero-Marah, V., Ragin, C., & Llanos, A. A. M. (2023). Delayed breast cancer presentation, diagnosis, and treatment in Kenya. *Breast Cancer Research and Treatment*, 202(3), 515–527. <https://doi.org/10.1007/s10549-023-07067-y>
- Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2023). Biomarkers in Cancer Detection, Diagnosis, and Prognosis. *Sensors*, 24(1), 37. <https://doi.org/10.3390/s24010037>
- Dasman, H. (2021). *Penelitian Analisis Survival*. Mitra Cendikia Media.
- Dasman, H., Harahap, W., & Khambri, D. (2021). *Analysis Predictors of the Outcome of Adjuvant of Hormone Therapy on Estrogen Receptor-positive Breast Cancer in Indonesia*. 9, 847–851.
- Derouane, F., van Marcke, C., Berlière, M., Gerday, A., Fellah, L., Leconte, I., Van Bockstal, M. R., Galant, C., Corbet, C., & Duhoux, F. P. (2022). Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine. *Cancers*, 14(16), 3876. <https://doi.org/10.3390/cancers14163876>
- Dinas Kesehatan Kota Padang. (2022). *Profil Kesehatan Kota Padang Tahun 2022*. Dinas Kesehatan Kota Padang.
- Dipiro, J., Schwinghammer, T., & Dipiro, C. (2015). *Pharmacotherapy Handbook Ninth Edition-Section 4 Chapter 19*. The McGraw-Hill Companies, Inc.
- Dipiro, J., Yee, G., Posey, M., Haines, S., Nolin, T., & Ellingrod, V. (2020a). Pharmacotherapy: A Pathophysiologic Approach, 11th Edition. In *Annals of Pharmacotherapy* (11th ed.). McGraw Hill. <https://doi.org/10.1345/aph.1h160>
- Djarmiko, A., Octovianus, J., Fortunata, N., & Andaru, I. (2013). Profil Cancer Delay pada Kasus Kanker Payudara di RS Onkologi Surabaya. *Indonesian Journal of Cancer*, 7(2), 47–52.

Drummond, M. F. (2015). *Methods For The Economic Evaluation Of Health Care Programmes*. Oxford University Press.

Ebrahim, M., Sedky, A. A. H., & Mesbah, S. (2023). Accuracy Assessment of Machine Learning Algorithms Used to Predict Breast Cancer. *Data*, 8(2), 35. <https://doi.org/10.3390/data8020035>

Ehsan, A. N., Wu, C. A., Minasian, A., Bass, M., Sana, H., Patel, A., Pace, L., Mekary, R. A., & Ranganathan, K. (2024). Evaluation of Financial Interventions in Breast Cancer Care Worldwide: A Systematic Review. *Plastic and Reconstructive Surgery - Global Open*, 12(5), e5683. <https://doi.org/10.1097/GOX.0000000000005683>

Ehsan, A. N., Wu, C. A., Minasian, A., Singh, T., Bass, M., Pace, L., Ibbotson, G. C., Bempong-Ahun, N., Pusic, A., Scott, J. W., Mekary, R. A., & Ranganathan, K. (2023). Financial Toxicity Among Patients With Breast Cancer Worldwide. *JAMA Network Open*, 6(2), e2255388. <https://doi.org/10.1001/jamanetworkopen.2022.55388>

Eichler, H., Kong, S., Gerth, W., Mavros, P., & Jönsson, B. (2004). Use Of Cost-Effectiveness Analysis In Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected To Emerge? *Value in Health*, 7(5), 518–528. <https://doi.org/10.1111/j.1524-4733.2004.75003.x>

El-Tanani, Y., El-Tanani, M., Rabbani, S. A., Babiker, R., & Satyam, S. M. (2025). Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence. *Science Progress*, 108(3). <https://doi.org/10.1177/00368504251362350>

Erfani, P., Bhangdia, K., Stauber, C., Mugunga, J. C., Pace, L. E., & Fadelu, T. (2021). Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review. *The Oncologist*, 26(8), e1406–e1417. <https://doi.org/10.1002/onco.13841>

EuroQol Research Foundation. (2019). *EQ-5D-5L User Guide : Basic Information On How To Use The EQ-5D-5L Instrument*. <https://euroqol.org/publications/user-guides/>.

Fei, C., DeRoo, L. A., Sandler, D. P., & Weinberg, C. R. (2013). Menopausal symptoms and the risk of young-onset breast cancer. *European Journal of Cancer*, 49(4), 798–804. <https://doi.org/10.1016/j.ejca.2012.08.030>

Feng, B., Liu, T., Feng, Y., Huang, J., & Qin, J. (2024). From sensitivity to public health: integrating cfMeDIP-seq into early breast cancer detection strategies. *Journal of Translational Medicine*, 22(1), 1083. <https://doi.org/10.1186/s12967-024-05827-y>

Filis, P., Filis, N., Foukakis, T., & Matikas, A. (2026). Progression-free survival 2 (PFS2) as a surrogate endpoint for overall survival (OS) in breast cancer randomized controlled

clinical trials. *ESMO Open*, 11(2), 106062.
<https://doi.org/10.1016/j.esmoop.2026.106062>

Finitzis, D., Pellowski, J., Medina, T., Fox, M., & Kalichaman, S. (2016). Visual Analogue Scale (VAS) Measurement Of Antiretroviral Adherence In People Living With HIV (PLWH): A Meta-Analysis. *J Behav Med*, 39(6), 1043–1055.

Fitria, N. (2023). *Analisis Farmakoekonomi Penggunaan Kombinasi Metformin Dan Glimepiride: A Cost-Effectiveness Analysis*.

Fokas, E., Williams, H., Diefenhardt, M., Lin, S., Qin, L.-X., Piso, P., Dapper, H., Germer, C.-T., Grützmann, R., Tim Friede, J., Joshua Smith, J., Saltz, L. B., Wu, A. J., Weiser, M. R., Omer, D., Ghadimi, M., Hofheinz, R.-D., Garcia-Aguilar, J., & Rödel, C. (2024). Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials. *European Journal of Cancer*, 210, 114291.
<https://doi.org/10.1016/j.ejca.2024.114291>

Geremew, H., Golla, E. B., Simegn, M. B., Abate, A., Ali, M. A., Kumbi, H., Wondie, S. G., Mengstie, M. A., & Tilahun, W. M. (2024a). Late-stage diagnosis: The driving force behind high breast cancer mortality in Ethiopia: A systematic review and meta-analysis. *PLOS ONE*, 19(7), e0307283. <https://doi.org/10.1371/journal.pone.0307283>

Gheorghe, A., Maringe, C., Spice, J., Purushotham, A., Chalkidou, K., Rachet, B., Sullivan, R., & Aggarwal, A. (2021). Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK. *European Journal of Cancer*, 152, 233–242.
<https://doi.org/10.1016/j.ejca.2021.04.019>

Gjerloev, A., Impelluso, G., Grieco, L., Jani, Y., Pagel, C., & Crowe, S. (2025). A configurable discrete event simulation to model patient flow along cancer pathways. *Journal of the Operational Research Society*, 1–19.
<https://doi.org/10.1080/01605682.2025.2557921>

Godiveau, M., Jahanmohan, J., Abrial, C., & Durando, X. (2025). Chemotherapy-induced peripheral neuropathy in patients with breast cancer treated with taxanes (Review). *Oncology Letters*, 30(5), 1–11. <https://doi.org/10.3892/ol.2025.15254>

Gokcek, S., Uzun, M., & Unek, I. (2026). Ki-67 and Platelet-to-Lymphocyte Ratio (PLR) as Predictors of Progression-Free Survival in Metastatic Breast Cancer Receiving CDK4/6 Inhibitors: Clinical Implications. *Cancer Management and Research*, Volume 18, 1–7. <https://doi.org/10.2147/CMAR.S584786>

Gonzalez, L., Bardach, A., Palacios, A., Peckaitis, C., Ciapponi, A., Pichón-Riviere, A., & Augustovski, F. (2021). Health-Related Quality of Life in Patients with Breast Cancer

in Latin America and the Caribbean: A Systematic Review and Meta-Analysis. *The Oncologist*, 26(5), e794–e806. <https://doi.org/10.1002/onco.13709>

Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, H. J., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Hurvitz, S. A., Jankowitz, R. C., Javid, S. H., Krishnamurthy, J., ... Kumar, R. (2023). NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. *J Natl Compr Canc Netw*, 21(6), 594–608. <https://doi.org/10.6004/jnccn.2023.0031>

Gray, L. A., Hernandez Alava, M., & Wailoo, A. J. (2021). Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer. *BMC Cancer*, 21(1), 1237. <https://doi.org/10.1186/s12885-021-08964-5>

Grewal, U. S., & Kurzrock, R. (2025). Mucin-1: a promising pan-cancer therapeutic target. *Npj Precision Oncology*, 9(1), 218. <https://doi.org/10.1038/s41698-025-01016-2>

Grusdat, N. P., Stäuber, A., Tolkmitt, M., Schnabel, J., Schubotz, B., Wright, P. R., & Schulz, H. (2022). Routine cancer treatments and their impact on physical function, symptoms of cancer-related fatigue, anxiety, and depression. *Supportive Care in Cancer*, 30(5), 3733–3744. <https://doi.org/10.1007/s00520-021-06787-5>

Harlan, J. (2017). *Analisis Survival*. Penerbit Gunadarma.

Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007). American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. *J Clin Oncol*, 25(33), 5287–5312. <https://doi.org/10.1200/JCO.2007.14.2364>

Hernandez, A., Benitez, V., Cardenas, J., Giner, M., Chico, J., & Hernandez, J. (2019). Factors Predicting Local Relapse And Survival In Patients Treated With Surgery For Breast Cancer. *Asian Journal of Surgery*, 42(7), 755–760.

Hill, H., Roadevin, C., Duffy, S., Mandrik, O., & Brentnall, A. (2024). Cost-Effectiveness of AI for Risk-Stratified Breast Cancer Screening. *JAMA Network Open*, 7(9), e2431715. <https://doi.org/10.1001/jamanetworkopen.2024.31715>

Hölzel, D., Schlesinger-Raab, A., Schubert-Fritschle, G., & Halfter, K. (2025). Prolonged time to breast cancer surgery and the risk of metastasis: an explorative simulation analysis using epidemiological data from Germany and the USA. *Breast Cancer Research and Treatment*, 211(1), 151–160. <https://doi.org/10.1007/s10549-025-07630-9>

Hoveling, L. A., Heuken, L. P., Harfst, T., Schuurman, M. S., van Asselt, K. M., Siesling, S., & Bode, C. (2025). Understanding delays in breast cancer diagnosis in Africa: Key

insights and contributing factors. *International Journal of Cancer*, 157(9), 1830–1840.
<https://doi.org/10.1002/ijc.70008>

Hutajulu, S. H., Prabandari, Y. S., Bintoro, B. S., Wiranata, J. A., Widiastuti, M., Suryani, N. D., Saptari, R. G., Taroeno-Hariadi, K. W., Kurnianda, J., Purwanto, I., Hardianti, M. S., & Allsop, M. J. (2022a). Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study. *PLOS ONE*, 17(1), e0262468. <https://doi.org/10.1371/journal.pone.0262468>

Hutchinson, B., Watts, R., Nyangasi, M., Anderson, B. O., Chepchumba, J., Wangia, E., Jalang'o, R., Mwenda, V., Yerramilli, P., Lee Kuguru, T., Kabubei, K. M., Gordillo-Tobar, A., Meheus, F., Meyer, C., Ilbawi, A., & Nugent, R. (2024). An economic evaluation of breast cancer interventions in Kenya. *EClinicalMedicine*, 77, 102894. <https://doi.org/10.1016/j.eclinm.2024.102894>

Ibrahim, E. Y., Munshani, S., Domenicano, I., Rodwin, R., Nowak, R. J., Pusztai, L., Lustberg, M., & Ehrlich, B. E. (2022). A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. *PLOS ONE*, 17(10), e0275648. <https://doi.org/10.1371/journal.pone.0275648>

Icanervilia, A., Choridah, L., Van Asselt, A., Vervoort, J., Postma, M., Rengganis, A., & Kardinah, K. (2023). Early Detection of Breast Cancer in Indonesia: Barriers Identified in a Qualitative Study. *Asian Pacific Journal of Cancer Prevention*, 24(8), 2749–2755. <https://doi.org/10.31557/APJCP.2023.24.8.2749>

Inayati, K. dan, & Purnami, S. (2015). Analisis Survival Nonparametrik Pada Pasien Kanker Serviks Di RSUD Dr. Soetomo Surabaya Menggunakan Metode Kaplan Meier Dan Uji Log Rank. *Jurnal Sains Dan Seni ITS*, 4, 2337–3520.

Incoronato, M., Grimaldi, A. M., Mirabelli, P., Cavaliere, C., Parente, C. A., Franzese, M., Staibano, S., Iardi, G., Russo, D., Soricelli, A., Catalano, O. A., & Salvatore, M. (2019). Circulating miRNAs in Untreated Breast Cancer: An Exploratory Multimodality Morpho-Functional Study. *Cancers*, 11(6), 876. <https://doi.org/10.3390/cancers11060876>

International Agency for Research on Cancer. (2020). *Global Burden of Cancer Study (GLOBOCAN)*.

Janatolmakan, M. et al. (2026). Factors Associated with Delays in Breast Cancer Diagnosis in Low- and Middle-income Countries: A Scoping Review. *Nternational Journal of Community Based Nursing and Midwifery*, 14, 22–42.

Jassem, J., Ozmen, V., Bacanu, F., Drobnienė, M., Eglitis, J., Lakshmaiah, K. C., Kahan, Z., Mardiak, J., Pieńkowski, T., Semiglazova, T., Stamatovic, L., Timcheva, C., Vasovic, S., Vrbanc, D., & Zaborek, P. (2014). Delays in diagnosis and treatment of breast

cancer: a multinational analysis. *European Journal of Public Health*, 24(5), 761–767.
<https://doi.org/10.1093/eurpub/ckt131>

Józwiak, K., Nguyen, V. H., Sollfrank, L., Linn, S. C., & Hauptmann, M. (2024). Cox proportional hazards regression in small studies of predictive biomarkers. *Scientific Reports*, 14(1), 14232. <https://doi.org/10.1038/s41598-024-64573-9>

Jung, H. H., Kim, J.-Y., Cho, E. Y., Lee, J. E., Kim, S. W., Nam, S. J., Park, Y. H., Ahn, J. S., & Im, Y.-H. (2023). A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. *International Journal of Molecular Sciences*, 24(21), 15576. <https://doi.org/10.3390/ijms242115576>

Juwita, D., Almahdy, & Afdila, R. (2019). Penilaian Kualitas Hidup Terkait Kesehatan Pasien Kanker Payudara di RSUP Dr. M. Djamil Padang, Indonesia. *Jurnal Ilmu Kefarmasian Indonesia*, 17(1), 114–119. <https://doi.org/10.35814/jifi.v17i1.682>

Kaiser, C. G., Dietzel, M., Vag, T., Rübenhaller, J., Froelich, M. F., & Tollens, F. (2021). Impact of specificity on cost-effectiveness of screening women at high risk of breast cancer with magnetic resonance imaging, mammography and ultrasound. *European Journal of Radiology*, 137, 109576. <https://doi.org/10.1016/j.ejrad.2021.109576>

Kamau, B., Shulimovich, M., & Samridhi, S. (2025). The Impact of Novel Therapies on Quality-of-Life in Triple-Negative Breast Cancer: A Systematic Review of Clinical Trials. *Cancers*, 17(20), 3307. <https://doi.org/10.3390/cancers17203307>

Kaur, M. N., Yan, J., Klassen, A. F., David, J. P., Pieris, D., Sharma, M., Bordeleau, L., & Xie, F. (2022). A Systematic Literature Review of Health Utility Values in Breast Cancer. *Medical Decision Making*, 42(5), 704–719. <https://doi.org/10.1177/0272989X211065471>

Kementerian Kesehatan RI. (2013). *Pedoman Penerapan Kajian Farmakoekonomi*. Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan RI. (2016a). *Bulan Peduli Kanker Payudara (Breast Cancer Awareness Month)*. http://www.depkes.go.id/resources/download/pusdatin/infodatin/InfoDatinBulanPeduliKankerPayudara_2016.pdf

Kementerian Kesehatan RI. (2016b). *Pedoman Teknis Analisis Farmakoekonomi Di Fasilitas Kesehatan*. Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan RI. (2017a). *Buku Panduan Penilaian Teknologi Kesehatan : Efektivitas Klinis dan Evaluasi Ekonomi*. Kementerian Kesehatan Republik Indonesia.

- Kementerian Kesehatan RI. (2017b). *Buku Panduan Penilaian Teknologi Kesehatan : Efektivitas Klinis dan Evaluasi Ekonomi*. Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan RI. (2019a). *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara*. Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan RI. (2020). *Modul Pelatihan Analisis Farmakoekonomi Di Pelayanan Kesehatan*. Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan RI. (2021). Profil Kesehatan Indonesia Tahun 2020. In *Kementerian Kesehatan Republik Indonesia*. Kementerian Kesehatan Republik Indonesia. <https://doi.org/10.1524/itit.2006.48.1.6>
- Kementerian Kesehatan RI. (2022a). *Deteksi Dini Kanker: Mengapa dan Bagaimana?* Kementerian Kesehatan Republik Indonesia. https://yankes.kemkes.go.id/view_artikel/173/deteksi-dini-kanker-mengapa-dan-bagaimana#
- Kementerian Kesehatan RI. (2022b). *Kanker Payudara Paling Banyak Di Indonesia, Kemenkes Targetkan Pemerataan Layanan Kesehatan*. <https://sehatnegeriku.kemkes.go.id/baca/umum/20220202/1639254/kanker-payudara-paling-banyak-di-indonesia-kemenkes-targetkan-pemerataan-layanan-kesehatan/>
- Kementerian Kesehatan RI. (2022c). *Pedoman Umum Penilaian Teknologi Kesehatan Di Indonesia*. Lembaga Penerbit BKPK.
- Khan, Y., Verhaeghe, N., Monten, C., Vanthomme, K., Gadeyne, S., Devleesschauwer, B., Verdoodt, F., Peacock, H. M., & De Smedt, D. (2025). Subtype-specific health and economic impact of delayed breast cancer diagnosis during the early COVID-19 pandemic in Belgium: a Markov model analysis. *Breast Cancer Research*, 28(1), 41. <https://doi.org/10.1186/s13058-025-02207-2>
- Kleinbaum, D., & Klein, M. (2012). *Survival Analysis A Self Learning Text Third Edition*. Springer.
- Ko, E., Valadez Galindo, A., Avila, M., Wells, K. J., Van Bebbber, A., Gamino, M., Martinez, J., & Cartmell, A. (2025). Cancer-related financial toxicity among Latinas with breast cancer in a rural area of the United States: a qualitative study. *BMC Women's Health*, 25(1), 182. <https://doi.org/10.1186/s12905-025-03692-5>
- Kregting, L. M., Vrancken Peeters, N. J. M. C., Clarijs, M. E., Koppert, L. B., Korfage, I. J., & van Ravesteyn, N. T. (2024a). Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness. *International Journal of Cancer*, 155(1), 117–127. <https://doi.org/10.1002/ijc.34899>

- Kunst, N., Wang, S., Hood, A., Mougalian, S., DiGiovanna, M., Adelson, K., & et al. (2020). Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer. *JAMA Network Open*, 3(11), e2027074. <https://doi.org/10.1001/jamanetworkopen.2020.27074>
- Kuthari, R., Damor, R., & Shringarpure, K. (2025). Mixed Methods Study of Care Pathway and Delay in Obtaining Health Services by Breast Cancer Patients in India. *Asian Pacific Journal of Cancer Prevention*, 26(6), 2097–2107. <https://doi.org/10.31557/APJCP.2025.26.6.2097>
- Lai, J.-I., Chao, T.-C., Liu, C.-Y., Huang, C.-C., & Tseng, L.-M. (2022). A systemic review of taxanes and their side effects in metastatic breast cancer. *Frontiers in Oncology*, 12. <https://doi.org/10.3389/fonc.2022.940239>
- Lebedeva, V., Ebbinghaus, M., Hidalgo, J. V., Hardt, O., & Pfeifer, R. (2025). Triple-Negative Breast Cancer Unveiled: Bridging Science, Treatment Strategy, and Economic Aspects. *International Journal of Molecular Sciences*, 26(19), 9714. <https://doi.org/10.3390/ijms26199714>
- Lee, S., Olvera, R. G., Shiu-Yee, K., Rush, L. J., Tarver, W. L., Blevins, T., McAlearney, A. S., Andersen, B. L., Paskett, E. D., Carson, W. E., Chen, J., & Obeng-Gyasi, S. (2024). Short-term and long-term financial toxicity from breast cancer treatment: a qualitative study. *Supportive Care in Cancer*, 32(1), 24. <https://doi.org/10.1007/s00520-023-08199-z>
- Leon-Ferre, R. A., Dimitroff, K., Yau, C., Giridhar, K. V., Mukhtar, R., Hirst, G., Hylton, N., Perlmutter, J., DeMichele, A., Yee, D., van 't Veer, L., Rugo, H., Symmans, W. F., Goetz, M. P., Esserman, L., & Boughey, J. C. (2025). Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. *Breast Cancer Research*, 27(1), 115. <https://doi.org/10.1186/s13058-025-02070-1>
- Li, J., Zhou, Z., Dong, J., Fu, Y., Li, Y., Luan, Z., & Peng, X. (2021). Predicting breast cancer 5-year survival using machine learning: A systematic review. *PLOS ONE*, 16(4), e0250370. <https://doi.org/10.1371/journal.pone.0250370>
- Lima, D. A. N. de, Pelloso, F. C., Pereira, E. da C. A., Carvalho, M. D. de B., Camparoto, C. W., Ribeiro, H. F., Stevanato, K. P., Borghesan, D. H. P., Tavares, I. M., Consolaro, M. E. L., Cuman, R. K. N., Marques, V. D., Alarcão, A. C. J., Pujals, C., Pedroso, R. B., & Pelloso, S. M. (2025). Delay in Diagnosis and Treatment of Breast Cancer: Regional Disparities. *Cancers*, 17(22), 3612. <https://doi.org/10.3390/cancers17223612>

- Lin, Y., Gao, G., Yang, X., Zhu, T., Zheng, X., Ji, F., & et al. (2022a). Neoadjuvant Therapy In Triple-Negative Breast Cancer: A Systematic Review And Network Meta-Analysis. *Breast (Edinburgh, Scotland)*, 66, 126–135. <https://doi.org/10.1016/j.breast.2022.08.006>
- Liu, J., He, C., & Zhao, J. (2025). Analysis of Serum Soluble Endoglin and s-CD105 Levels in Relation to Postoperative Recurrence and Metastasis in Breast Cancer Patients Treated with Modified Radical Mastectomy. *International Journal of Women's Health, Volume 17*, 1597–1604. <https://doi.org/10.2147/IJWH.S515952>
- Liu, K., Zheng, R., Zhang, J., Wang, S., Jin, Y., Wu, F., Wang, J., Wang, S., Zha, X., & Tang, Y. (2025). Predicting relative efficacy of anthracyclines and taxanes in breast cancer neoadjuvant AC-T chemotherapy using longitudinal MRI radiomic model. *Frontiers in Oncology*, 15. <https://doi.org/10.3389/fonc.2025.1544833>
- Liu, M., Hu, X., Wang, Y., & Shi, D. (2018). Survive Or Perish: Investigating The Life Cycle Of Academic Journals From 1950 to 2013 Using Survival Analysis Methods. *Journal of Informetrics*, 12, 344–364.
- Liu, W., Ren, S., Yang, L., Xiao, Y., Zeng, C., Chen, C., Wu, F., & Hu, Y. (2023). The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study. *International Journal of Surgery*, 109(11), 3519–3526. <https://doi.org/10.1097/JS9.0000000000000650>
- Liu, Y., Fan, L., Wang, Z., & Shao, Z. (2023a). Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study. *The Oncologist*, 28(1), 86-e76. <https://doi.org/10.1093/oncolo/oyac223>
- Liu, Y., Fan, L., Wang, Z., & Shao, Z. (2023b). Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study. *The Oncologist*, 28(1), 86-e76. <https://doi.org/10.1093/oncolo/oyac223>
- Luu, T. N. N., Dinh, D. X., Tran, T. X., Tran, T. B., Tran, H. T., Pham, K. H. T., & Nguyen, H. T. T. (2024). Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study. *PLOS ONE*, 19(5), e0303011. <https://doi.org/10.1371/journal.pone.0303011>
- Mai, N., Myers, S., Shen, S., Downs-Canner, S., Robson, M., Norton, L., Chen, Y., Traina, T., & Abuhadra, N. (2024). Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer. *Npj Breast Cancer*, 10(1), 39. <https://doi.org/10.1038/s41523-024-00643-5>

- Masucci, L., Beca, J., Sabharwal, M., & Hoch, J. S. (2017). Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR). *Pharmacoeconomics - Open*, 1(4), 255–263. <https://doi.org/10.1007/s41669-017-0018-3>
- Masuku, S. D., Mandrik, O., Mdege, N. D., Mishra, G., Muwonge, R., Meyer-Rath, G., Lince-Deroche, N., & Brennan, A. (2025). Breast Cancer Screening Using Clinical Breast Examination: A Cost-Effectiveness Analysis for South Africa. *Value in Health Regional Issues*, 49, 101127. <https://doi.org/10.1016/j.vhri.2025.101127>
- Mazzitelli, C., Santini, D., Corradini, A. G., Zamagni, C., Trerè, D., Montanaro, L., & Taffurelli, M. (2023). Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going. *Diagnostics*, 13(7), 1241. <https://doi.org/10.3390/diagnostics13071241>
- McGarvey, N., Gitlin, M., Fadli, E., & Chung, K. C. (2022a). Increased healthcare costs by later stage cancer diagnosis. *BMC Health Services Research*, 22(1), 1155. <https://doi.org/10.1186/s12913-022-08457-6>
- McGarvey, N., Gitlin, M., Fadli, E., & Chung, K. C. (2022b). Increased healthcare costs by later stage cancer diagnosis. *BMC Health Services Research*, 22(1), 1155. <https://doi.org/10.1186/s12913-022-08457-6>
- Mertz, S., Benjamin, C., Girvalaki, C., Cardone, A., Gono, P., May, S. G., Comerford, E., Than, K.-S., Birch, K., Roach, M., Myers, S., Sasane, M., Lavi, L., Cameron, A., & Cardoso, F. (2022). Progression-free survival and quality of life in metastatic breast cancer: The patient perspective. *The Breast*, 65, 84–90. <https://doi.org/10.1016/j.breast.2022.07.006>
- Miller-Kleinhenz, J. M., Collin, L. J., Seidel, R., Reddy, A., Nash, R., Switchenko, J. M., & McCullough, L. E. (2021). Racial Disparities in Diagnostic Delay Among Women With Breast Cancer. *Journal of the American College of Radiology*, 18(10), 1384–1393. <https://doi.org/10.1016/j.jacr.2021.06.019>
- Minarini, E. J. C. da S., Pessanha, R. M., Schuab, S. I. P. de C., D'Agostini, N. S., Santos, V. O., Grassi, J., Grippa, W. R., Nunes, K. Z., & Lopes-Júnior, L. C. (2025). Health-Related Quality of Life in Newly Diagnosed Cancer Patients Prior to First Outpatient Chemotherapy: A Cross-Sectional Study. *SAGE Open Nursing*, 11. <https://doi.org/10.1177/23779608251367653>
- Miret, C., Orive, M., Sala, M., García-Gutiérrez, S., Sarasqueta, C., Legarreta, M. J., Redondo, M., Rivero, A., Castells, X., Quintana, J. M., Garin, O., Ferrer, M., Comas, M., Domingo, L., Macià, F., Roman, M., Romero, A., Barata, T., Diez de la Lastra, I., ... Troya, I. (2023). Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.

Quality of Life Research, 32(4), 989–1003. <https://doi.org/10.1007/s11136-022-03327-4>

Mital, S., & Nguyen, H. V. (2022). Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening. *BMC Cancer*, 22(1), 501. <https://doi.org/10.1186/s12885-022-09613-1>

Mittmann, N., Evans, W. K., Rocchi, A., Longo, C. J., Au, H.-J., Husereau, D., Leighl, N. B., Isogai, P. K., Krahm, M. D., Peacock, S., Marshall, D., Coyle, D., Malfair Taylor, S. C., Jacobs, P., & Oh, P. I. (2012). Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. *Value in Health*, 15(3), 580–585. <https://doi.org/10.1016/j.jval.2011.12.006>

Mobus, V., Lück, H., Ladda, E., Klare, P., Schmidt, M., Schneeweiss, A., & et al. (2021). Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). *European Journal of Cancer*, 156, 138–148. <https://doi.org/10.1016/j.ejca.2021.07.033>

Moding, E. J., Nabat, B. Y., Alizadeh, A. A., & Diehn, M. (2021). Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. *Cancer Discovery*, 11(12), 2968–2986. <https://doi.org/10.1158/2159-8290.CD-21-0634>

Monteiro, M. R., Nunes, N. C. C., Crespo, J., Abrahão, A. B. K., Buscacio, G., Lerner, L. C. C., Sermoud, L., Arakelian, R., Piotto, G., Lemos, C., Campos, R., Victorino, D., Andrade, P. M., Ferreira, T. A. V., Pecoraro, J. P., Meton, F., Gai, M. F., & Araujo, L. H. (2022). Patient-centered Outcomes in Breast Cancer: Description of EQ-5D-5L and EORTC-QLQ-BR23 Measurements in Real-world Data and Their Association With Survival. *Clinical Oncology*, 34(9), 608–616. <https://doi.org/10.1016/j.clon.2022.05.015>

Msoka, E. F., Abraham, M., Cyril, P. M., Serventi, F., Kavishe, A. A., Kitali, B. M., Saria, V. F., Bright, F. B., Henke, O., Masenga, G. G., Mulder, B. C., Blanchard, C., Joffe, M., Kantelhardt, E. J., Gutnik, L., & Mmbaga, B. T. (2025). Factors Contributing to Late Breast Cancer Diagnosis: A Qualitative Study on the Patient's Perspective in Tanzania. *BMC Women's Health*, 26(1), 34. <https://doi.org/10.1186/s12905-025-04213-0>

Mühlberger, N., Sroczynski, G., Gogollari, A., Jahn, B., Pashayan, N., Steyerberg, E., Widschwendter, M., & Siebert, U. (2021a). Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies. *The European Journal of Health Economics*, 22(8), 1311–1344. <https://doi.org/10.1007/s10198-021-01338-5>

Murray, N. P., & Aedo, S. (2025). Minimal Residual Disease in Breast Cancer: Tumour Microenvironment Interactions, Detection Methods and Therapeutic Approaches.

International Journal of Molecular Sciences, 26(23), 11346.
<https://doi.org/10.3390/ijms262311346>

- Nadira, C., Rizka, A., & Humaira, Z. (2023). Faktor Keterlambatan Pada Pasien Kanker Payudara Yang Berobat Di RSUCM Aceh Utara Tahun 2020 - 2021. *Jurnal Ilmiah Manusia Dan Kesehatan*, 6(1), 88–99. <https://doi.org/10.31850/makes.v6i1.1942>
- Nambaziira, R., Niteka, L. C., Dusengimana, J. M. V., Ruhumuriza, J., Bhangdia, K. P., Mugunga, J. C., Uwineza, M. L., Rugema, V., Erfani, P., Shyirambere, C., Shulman, L. N., Rabideau, M., & Pace, L. E. (2022). Health system costs of a breast cancer early diagnosis programme in a rural district of Rwanda: a retrospective, cross-sectional economic analysis. *BMJ Open*, 12(6), e062357. <https://doi.org/10.1136/bmjopen-2022-062357>
- Narulita, S. (2022). *Faktor-Faktor Yang Berhubungan Dengan Keterlambatan Pasien Kanker Payudara Datang Ke RSUP Dr. M. Djamil Padang*. Universitas Andalas.
- NCCN. (2023). *Guidelines for patients inflammatory-breast-patient.pdf*. National Comprehensive Cancer Network Foundation.
- Ng, B., Puspitaningtyas, H., Wiranata, J. A., Hutajulu, S. H., Widodo, I., Anggorowati, N., Sanjaya, G. Y., Lazuardi, L., & Sripan, P. (2023). Breast cancer incidence in Yogyakarta, Indonesia from 2008–2019: A cross-sectional study using trend analysis and geographical information system. *PLOS ONE*, 18(7), e0288073. <https://doi.org/10.1371/journal.pone.0288073>
- Nguyen, L. B., Vu, L. G., Le, T. T., Nguyen, X. T., Dao, N. G., Nguyen, D. C., Huyen Thi Dang, T., Vu, T. M. T., Boyer, L., Fond, G., Auquier, P., Latkin, C. A., Zhang, M. W. B., Ho, R. C. M., & Ho, C. S. H. (2023). Impact of interventions on the quality of life of cancer patients: a systematic review and meta-analysis of longitudinal research. *Health and Quality of Life Outcomes*, 21(1), 112. <https://doi.org/10.1186/s12955-023-02189-9>
- Nguyen, S. M., Nguyen, Q. T., Nguyen, L. M., Pham, A. T., Luu, H. N., Tran, H. T. T., Tran, T. V., & Shu, X. (2021a). Delay in the diagnosis and treatment of breast cancer in Vietnam. *Cancer Medicine*, 10(21), 7683–7691. <https://doi.org/10.1002/cam4.4244>
- Nobre, A. R., Dalla, E., Yang, J., Huang, X., Wullkopf, L., Risson, E., Razghandi, P., Anton, M. L., Zheng, W., Seoane, J. A., Curtis, C., Kenigsberg, E., Wang, J., & Aguirre-Ghisso, J. A. (2022). ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung. *Nature Cancer*, 3(10), 1165–1180. <https://doi.org/10.1038/s43018-022-00424-8>
- Nurfain, & Purnami, S. (2017). Analisis Regresi Cox Extended Pada Pasien Kusta Di Kecamatan Brondong Kabupaten Lamongan. *Jurnal Sains Dan Seni ITS*, 6(1), 1–7.

- Osborne, A., Adnani, Q. E. S., & Ahinkorah, B. O. (2025). Breast cancer incidence in Indonesia: a sex-disaggregated analysis using WHO health equity assessment toolkit data. *BMC Cancer*, 25(1), 986. <https://doi.org/10.1186/s12885-025-14332-4>
- O'Shaughnessy, J., Gradishar, W., O'Regan, R., & Gadi, V. (2023). Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics. *Clinical Breast Cancer*, 23(4), 350–362. <https://doi.org/10.1016/j.clbc.2023.03.007>
- Owaid, H., & Jewad, A. (2025). Efficacy of Cancer Antigen 15-3, Trefoil Factor-3, and Human Epididymis Protein-4 in the Diagnosis of Breast Cancer. *Archives of Breast Cancer*, 12(3), 303–310. <https://doi.org/10.32768/abc.8773311177538>
- Pandey, S. N., Babu, M. A., Ali, H., H. M., Maharana, L., Goyal, K., Rana, M., & Imran, M. (2025). MUC1 as a diagnostic biomarker and siRNA-based therapeutic target in breast cancer: A clinical chemistry perspective. *Clinica Chimica Acta*, 576, 120387. <https://doi.org/10.1016/j.cca.2025.120387>
- Pappot, H., Jørgensen, A., Bjørum, A. H., Jakobsen, C. B., Jørgensen, C. U., Høeg, B. L., Bidstrup, P., Knop, A., & Bentsen, L. (2025). Understanding quality of life in Danish women with metastatic breast cancer undergoing multiple treatments. *Acta Oncologica*, 64, 292–302. <https://doi.org/10.2340/1651-226X.2025.42446>
- Park, K. H., Loibl, S., Sohn, J., Park, Y. H., Jiang, Z., Tadjoeidin, H., Nag, S., Saji, S., Md. Yusof, M., Villegas, E. M. B., Lim, E. H., Lu, Y.-S., Ithimakin, S., Tseng, L.-M., Dejthevaporn, T., Chen, T. W.-W., Lee, S. C., Galvez, C., Malwinder, S., ... Harbeck, N. (2024). Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer. *ESMO Open*, 9(5), 102974. <https://doi.org/10.1016/j.esmoop.2024.102974>
- Paveliu, M., Olariu, E., Caplescue, R., Oluboyede, Y., Aron, I., & Ernu, S. (2021). Estimating An EQ-5D-3L Value Set For Romania Using Time Trade-Off. *Int J Environ Res Public Health*, 18(14), 7415.
- Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996). A simulation study of the number of events per variable in logistic regression analysis. *Journal of Clinical Epidemiology*, 49(12), 1373–1379. [https://doi.org/10.1016/S0895-4356\(96\)00236-3](https://doi.org/10.1016/S0895-4356(96)00236-3)
- Perwitasari, D. A., Candradewi, S. F., Purba, F. D., & Septiantoro, B. P. (2023). Mapping functions of cancer patients' quality of life in Indonesia: from EORTC-Q1Q-C-30 to EQ-5D-5L – Journal of Advanced Pharmacy Education and Research, 13(3), 19–22. <https://doi.org/10.51847/avg60W3aR5>

- Perwitasari, D. A., Purba, F. D., Candradewi, S. F., Dania, H., Muhammad Irham, L., Noor Faridah, I., & Septiantoro, B. P. (2023). Quality of Life of Cancer Patients during Chemotherapy in Indonesia: A Comparison of EORTC QLQ-C30 and EQ-5D-5L, Based on Patients' Characteristics. *International Journal of Clinical Practice*, 2023, 1–9. <https://doi.org/10.1155/2023/9357299>
- Petrovici, I., Ionica, M., & Neagoe, O. C. (2021a). Economic Crisis: A Factor for the Delayed Diagnosis of Breast Cancer. *International Journal of Environmental Research and Public Health*, 18(8), 3998. <https://doi.org/10.3390/ijerph18083998>
- Petrovici, I., Ionica, M., & Neagoe, O. C. (2021b). Economic Crisis: A Factor for the Delayed Diagnosis of Breast Cancer. *International Journal of Environmental Research and Public Health*, 18(8), 3998. <https://doi.org/10.3390/ijerph18083998>
- Petrovici, I., Ionica, M., & Neagoe, O. C. (2021c). Economic Crisis: A Factor for the Delayed Diagnosis of Breast Cancer. *International Journal of Environmental Research and Public Health*, 18(8), 3998. <https://doi.org/10.3390/ijerph18083998>
- Phipps, A. I., Ichikawa, L., Bowles, E. J. A., Carney, P. A., Kerlikowske, K., Miglioretti, D. L., & Buist, D. S. M. (2010). Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates. *Maturitas*, 67(1), 60–66. <https://doi.org/10.1016/j.maturitas.2010.04.015>
- Pratama, W., Wetan, Y., & Widiana, I. (2021). Faktor yang mempengaruhi keterlambatan pengobatan kanker payudara: sebuah tinjauan sistematik. *Intisari Sains Medis | Intisari Sains Medis*, 12(1), 346–355. <https://doi.org/10.15562/ism.v12i1.927>
- Purba, F., Hunfeld, J., Iskandarsyah, A., Fitriana, T., Sadarjoen, S., Ramos-Goñi, J., Passchier, J., & Busschbach, J. (2017a). The Indonesian EQ-5D-5L Value Set. *PharmacoEconomics*, 35(11), 1153–1165. <https://doi.org/10.1007/s40273-017-0538-9>
- Purba, F., Hunfeld, J., Iskandarsyah, A., Fitriana, T., Sadarjoen, S., Ramos-Goñi, J., Passchier, J., & Busschbach, J. (2017b). The Indonesian EQ-5D-5L Value Set. *PharmacoEconomics*, 35(11), 1153–1165. <https://doi.org/10.1007/s40273-017-0538-9>
- Rajaram, N., Jaganathan, M., Muniandy, K., Rajoo, Y., Zainal, H., Rahim, N., Tajudeen, N. A., Zainal, N. H., Mohd Khairy, A., Abdul Wahab, M. Y., & Teo, S. H. (2023). Barriers to help-seeking for Malaysian women with symptoms of breast cancer: a mixed-methods, two-step cluster analysis. *BMC Health Services Research*, 23(1), 206. <https://doi.org/10.1186/s12913-023-09046-x>
- Ranawaka, S., Gunarathna, S., Gunasekera, S., Booth, C. M., Jalink, M., Carson, L. M., Berry, S., Gyawali, B., Seneviratne, S., & Wijeratne, D. T. (2024). Breast Cancer-Related Financial Toxicity in Sri Lanka: Insights From a Lower Middle-Income

Country With Free Universal Public Healthcare. *The Oncologist*, 29(2), e259–e265.
<https://doi.org/10.1093/oncolo/oyad259>

Rao, Dr. N. (2023). Clinical utility of serum CA15-3 in patients with breast cancer: A systematic review. *International Journal of Bioscience and Biochemistry*, 5(1), 01–05.
<https://doi.org/10.33545/26646536.2023.v5.i1a.32>

Rautenberg, T., Hodgkinson, B., Zerwes, U., & Downes, M. (2022). Meta-analysis of health state utility values measured by EuroQol 5-dimensions (EQ5D) questionnaire in Chinese women with breast cancer. *BMC Cancer*, 22(1), 52.
<https://doi.org/10.1186/s12885-021-09140-5>

Ren, W., Chen, M., Qiao, Y., & Zhao, F. (2022). Global guidelines for breast cancer screening: A systematic review. *The Breast*, 64, 85–99.
<https://doi.org/10.1016/j.breast.2022.04.003>

Ricvan, *, Nindrea, D., Aryandono, T., Lazuardi, L., & Dwiprahasto, I. (2019). Family History of Breast Cancer and Breast Cancer Risk between Malays Ethnicity in Malaysia and Indonesia: A Meta-Analysis. In *Iran J Public Health* (Vol. 48, Number 2). <http://ijph.tums.ac.ir>

Rodriguez-Tirado, C., Kale, N., Carlini, M. J., Shrivastava, N., Rodrigues, A. A., Khalil, B. D., Bravo-Cordero, J. J., Hong, Y., Alexander, M., Ji, J., Behbod, F., & Sosa, M. S. (2022). NR2F1 Is a Barrier to Dissemination of Early-Stage Breast Cancer Cells. *Cancer Research*, 82(12), 2313–2326. <https://doi.org/10.1158/0008-5472.CAN-21-4145>

RSUP Dr. Djamil Padang. (2021). *Laporan Rumah Sakit: 10 Besar Penyakit Terbanyak Per Tahun 2021*. <https://rsdjamil.co.id/laporan-rumah-sakit/>.

Ryu, J. M., Kang, D., Cho, J., Lee, J. E., Kim, S. W., Nam, S. J., Lee, S. K., Kim, Y. J., Im, Y.-H., Ahn, J. S., Park, Y. H., Kim, J.-Y., Lee, H., Kang, M., & Yu, J. H. (2023). Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level. *Journal of Breast Cancer*, 26(2), 126. <https://doi.org/10.4048/jbc.2023.26.e17>

Sari, Y., Rustini, R., Diana, D., & Hapsari, T. (2017). Audit Secara Prospektif terhadap Antimicrobial Stewardship Program pada Pasien Kanker Payudara di RSUP Dr. M. Djamil Padang. *Jurnal Sains Farmasi & Klinis*, 4(1), 88.
<https://doi.org/10.29208/jsfk.2017.4.1.204>

Schwinghammer, T., Dipiro, J., Ellingrod, V., & Dipiro, C. (2021). *Pharmacotherapy Handbook* (11th ed.). McGraw Hill.
<https://accesspharmacy.mhmedical.com/content.aspx?bookid=3012§ionid=253436562>

Shinden, Y., Kamimura, K., Hayashi, N., Nomoto, Y., Nagata, A., Eguchi, Y., Yano, H., Saho, H., Nakajo, A., Minami, K., Hirashima, T., Sasaki, K., Yoshinaka, H., Owaki, T., Tanimoto, A., Nakamura, M., & Otsuka, T. (2023). Relationship between Delayed Breast Cancer Diagnosis and Behavioral Economic Factors and Personality Characteristics. *Asian Pacific Journal of Cancer Prevention*, 24(10), 3437–3440. <https://doi.org/10.31557/APJCP.2023.24.10.3437>

Smeltzer, S. C. (2015). *Keperawatan Medikal-Bedah (Handbook For Brunner & Suddarth's Textbook Of Medical Surgical Nursing)* (12th ed.). EGC.

Smith, A. F., Frempong, S. N., Sharma, N., Neal, R. D., Hick, L., & Shinkins, B. (2022). An exploratory assessment of the impact of a novel risk assessment test on breast cancer clinic waiting times and workflow: a discrete event simulation model. *BMC Health Services Research*, 22(1), 1301. <https://doi.org/10.1186/s12913-022-08665-0>

Spasov, M., & Spasov, H. (2025). THE ROLE OF Ca 15-3 IN THE DIAGNOSIS AND SCREENING OF BREAST CANCER. *MEDIS – International Journal of Medical Sciences and Research*, 4(3), 25–29. <https://doi.org/10.35120/medisij0403025s>

Subedi, R., Houssami, N., Nickson, C., Nepal, A., Campbell, D., David, M., & Yu, X. Q. (2024). Factors influencing the time to diagnosis and treatment of breast cancer among women in low- and middle-income countries: A systematic review. *The Breast*, 75, 103714. <https://doi.org/10.1016/j.breast.2024.103714>

Sukma, S., Effendi, N., Harahap, W., & Dasman, H. (2022). *Risk Factors and Probability of Breast Cancer in Women in West Sumatera : A Case-Control Study*. 47(Ichb 2021), 141–147.

Susilowati, M., & Afiyanti, Y. (2021). The Socio-Demographic Factors Correlated with Financial Toxicity among Patients with Breast Cancer in Indonesia. *Journal of Public Health Research*, 10(1_suppl). <https://doi.org/10.4081/jphr.2021.2403>

Thavorncharoensap, M., Teerawattananon, Y., Natanant, S., Kulpeng, W., Yothasamut, J., & Werayingyong, P. (2013). Estimating The Willingness To Pay For A Quality- Adjusted Life Year In Thailand: Does The Context Of Health Gain Matter? *ClinicoEconomics and Outcomes Research*, 5(1), 29–36. <https://doi.org/10.2147/CEOR.S38062>

Therescova, C., Maribeth, A., & Rafli, R. (2022). Gambaran Diagnostic Delay Dan Treatment Delay Pasien Kanker Payudara Di Kota Padang. *Health and Medical Journal*, 5(1), 21–30. <https://doi.org/10.33854/heme.v5i1.1174>

Thom, H. (2022). Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be? *Applied Health Economics and Health Policy*, 20(3), 447–449. <https://doi.org/10.1007/s40258-021-00700-1>

- Tian, H., Ma, D., Tan, X., Yan, W., Wu, X., He, C., Zhong, L., Zhang, Y., Yu, B., Zhang, Y., & Qi, X. (2021). Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review. *Frontiers in Pharmacology*, 12. <https://doi.org/10.3389/fphar.2021.770663>
- Tollens, F., Baltzer, P. A. T., Dietzel, M., Rübenthaler, J., Froelich, M. F., & Kaiser, C. G. (2021). Cost-Effectiveness of Digital Breast Tomosynthesis vs. Abbreviated Breast MRI for Screening Women with Intermediate Risk of Breast Cancer—How Low-Cost Must MRI Be? *Cancers*, 13(6), 1241. <https://doi.org/10.3390/cancers13061241>
- Tonin, F., Aznar-Lou, I., Pontinha, V., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles Of Pharmacoeconomic Analysis: The Case Of Pharmacist-Led Interventions. *Pharmacy Practice*, 19(1), 1–10. <https://doi.org/10.18549/PharmPract.2021.1.2302>
- Tu, C., Zhong, Y., Li, H., Qi, H., Lu, Q., & He, X. (2026). A cost-effective breast cancer screening strategy for Urban China: Findings from a Shenzhen-based modeling study. *PLOS One*, 21(3), e0344253. <https://doi.org/10.1371/journal.pone.0344253>
- Ungvari, Z., Fekete, M., Buda, A., Lehoczki, A., Munkácsy, G., Scaffidi, P., Bonaldi, T., Fekete, J. T., Bianchini, G., Varga, P., Ungvari, A., & Györffy, B. (2025). Quantifying the impact of treatment delays on breast cancer survival outcomes: a comprehensive meta-analysis. *GeroScience*, 48(1), 1173–1187. <https://doi.org/10.1007/s11357-025-01719-1>
- Uygur, M. M., & Gümüş, M. (2021). The utility of serum tumor markers CEA and CA 15–3 for breast cancer prognosis and their association with clinicopathological parameters. *Cancer Treatment and Research Communications*, 28, 100402. <https://doi.org/10.1016/j.ctarc.2021.100402>
- van der Veer, E. L., Lameijer, J., Coolen, A. M. P., Bluekens, A. M. J., Nederend, J., Gielens, M., Voogd, A., & Duijm, L. (2023). Causes and consequences of delayed diagnosis in breast cancer screening with a focus on mammographic features and tumour characteristics. *European Journal of Radiology*, 167, 111048. <https://doi.org/10.1016/j.ejrad.2023.111048>
- Verhoeven, D., Siesling, S., Allemani, C., Roy, P. G., Travado, L., Bhoo-Pathy, N., Rhayns, C., Junkermann, H., Nakamura, S., Lasebikan, N., & Tucker, F. L. (2024a). High-value breast cancer care within resource limitations. *The Oncologist*, 29(7), e899–e909. <https://doi.org/10.1093/oncolo/oyae080>
- Vlataki, K., Antonouli, S., Kalyvioti, C., Lampri, E., Kamina, S., Mauri, D., Harissis, H. V., & Magklara, A. (2023). Circulating Tumor DNA in the Management of Early-Stage Breast Cancer. *Cells*, 12(12), 1573. <https://doi.org/10.3390/cells12121573>

Wang, M., Wei, Z., Kong, J., & Zhao, H. (2024). Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients. *Diagnostic Pathology*, 19(1), 53. <https://doi.org/10.1186/s13000-024-01451-y>

WHO. (2003). *Who Guide to Cost-Effectiveness Analysis*.

WHO. (2023a). *Breast Cancer*. <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>

WHO. (2023b). *Global Breast Cancer Initiative Implementation Framework : Assessing, Strengthening and Scaling-Up of Services for the Early Detection and Management of Breast Cancer. Executive Summary*. World Health Organization.

Widya Ananda Arifin, Khasanah, U., Esyuananik, E., & Wahyu Wulan, D. (2025). Use of SADARI Educational Video Media on the Knowledge and Attitudes of Menopausal Women. *Journal of Health Sciences*, 18(01), 87–93. <https://doi.org/10.33086/jhs.v18i01.5927>

Wilkinson, A. N., Mainprize, J. G., Yaffe, M. J., Robinson, J., Cordeiro, E., Look Hong, N. J., Williams, P., Moideen, N., Renaud, J., Seely, J. M., & Rushton, M. (2025). Cost-Effectiveness of Breast Cancer Screening Using Digital Mammography in Canada. *JAMA Network Open*, 8(1), e2452821. <https://doi.org/10.1001/jamanetworkopen.2024.52821>

Wu, L., Wu, Z., & Liu, W. (2024). Exploring the Realization Level and the Obstacles Affecting Different Types of Ecological Product Value—A Typical Case from Zhejiang, China. *Sustainability*, 16(22), 9856. <https://doi.org/10.3390/su16229856>

Wu, T. (2024). A Bayesian Markov Framework for Modeling Breast Cancer Progression. *Mathematics*, 13(1), 65. <https://doi.org/10.3390/math13010065>

Yasril, & Kasjono, B. (2008). *Analisis Multivariat Untuk Penelitian Kesehatan Yogyakarta*. Mitra Cendekia Press.

Yosmar, R., Ningsih, L., & Ifmaily. (2020). Studi Analisa Efektivitas Biaya pada Pasien Kanker Payudara yang Menjalani Kemoterapi di RSUP Dr. M. Djamil Padang. *Jurnal Farmasi Higea*, 12(1).

Yuan, H., Sheen, M. A., Biggs, E., Mishra, M., Peeples, J., Saxena, R., & Haupt, C. (2024). Racial differences in degrees of side effects to taxane based chemotherapy in patients with breast cancer. *Journal of Clinical Oncology*, 42(16_suppl), e13726–e13726. https://doi.org/10.1200/JCO.2024.42.16_suppl.e13726

Yuliastuti, F., Andayani, T. M., Endarti, D., & Kristina, S. A. (2024). Cost determinant of chemotherapy in breast, cervical, and lung cancer in the era of National Health Insurance. *Pharmacy Practice*, 22(2), 1–10. <https://doi.org/10.18549/PharmPract.2024.2.2957>

Yusransyah, Kristina, S., Endarti, D., & Trung, V. (2023). Cost Effectiveness Of Cervical Cancer Prevention Strategies In Indonesia. *Pharmacy Practice*, 21(2), 1–5. <https://doi.org/10.18549/PharmPract.2023.2.2808>

Zheng, H.-L., Zhang, L.-K., Lv, C.-B., Xu, B.-B., Lin, J.-X., Zheng, C.-H., Huang, C.-M., & Xie, J.-W. (2024). Impact of dynamic changes of tumor marker in neoadjuvant chemotherapy-treated triple-negative gastric cancer patients: a multi-center study. *BMC Cancer*, 24(1), 1188. <https://doi.org/10.1186/s12885-024-12937-9>

Zubair, M., Wang, S., & Ali, N. (2021). Advanced Approaches to Breast Cancer Classification and Diagnosis. *Frontiers in Pharmacology*, 11. <https://doi.org/10.3389/fphar.2020.632079>

Zuo, D., Yang, L., Jin, Y., Qi, H., Liu, Y., & Ren, L. (2023). Machine learning-based models for the prediction of breast cancer recurrence risk. *BMC Medical Informatics and Decision Making*, 23(1), 276. <https://doi.org/10.1186/s12911-023-02377-z>

